Publication of BeAT-HF Clinical Study Results in the Journal of the American College of Cardiology (JACC)

Baroreflex Activation Therapy in Patients with Heart Failure with Reduced Ejection Fraction: BeAT-HF Study Results

Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT

J Am Coll Cardiol. 2020 Jul, 76 (1) 1-13.

Editorial Accompanying the JACC Publication of BeAT-HF Clinical Study Results

The Need to Innovate and Accelerate Clinical Trial Performance: BeAT the Clock

Januzzi JL, Ibrahim NE

J Am Coll Cardiol. 2020 Jul (1) 14-16.

BeAT-HF 2020 ESC Poster

Symptomatic Endpoint Responder Rates to BAROSTIM THERAPY

Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Zile MR, Galle E, Schafer J, Bahu MM

2020 ESC; August 29, 2020 Poster

BeAT-HF 2020 ESC Poster

Quality of Life Response to BAROSTIM THERAPY

Zannad F, Abraham WT, Lindenfeld J, Weaver FA, Galle E, Rogers T, Zile MR

2020 ESC; August 29, 2020 Poster

BeAT-HF 2020 ESC-HF Late Breaking Clinical Trial Presentation

Baroreflex Activation Therapy in Patients with Heart Failure and Reduced Ejection Fraction: Responder Rates and Quality of Life Measures Analyzed by Gender

Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Bahu MM, Grazette L, Zile MR

LBCT 2020 ESC-HF; June 19, 2020 Presentation

BeAT-HF 2020 ESC-HF Presentation

Impact of Left Ventricular Ejection Fraction and Atrial Fibrillation on Baroreflex Activation Therapy

Zile MR, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Grazette L, Lindenfeld J

2020 ESC-HF; June 19, 2020 Presentation

BeAT-HF 2020 ESC-HF Poster

BAROSTIM THERAPY in Patients with Heart Failure with a Reduced Ejection Fraction, Impact in Women

Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Zile MR, Galle E, Rogers T, Grazette L

2020 ESC-HF; June 19, 2020 Poster

BeAT-HF 2020 HRS Invited Presentation

Does Neuromodulation Using Baroreflex Activation Therapy (BAT) have Potential Application in HFpEF?

Zile MR

2020 HRS; July 31, 2020 Presentation

BeAT-HF 2020 HRS Poster

Cost-Impact Analysis Of Baroreflex Activation Therapy In Patients With Chronic Heart Failure In The United States

Zile MR, Schneider J, Davies S, Galle E, Stojanovic I, Bisognano J

2020 HRS; May 7, 2020 Poster

BeAT-HF 2020 HRS Presentation

Symptomatic Responder Rates To Barostim Therapy

Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Zile MR, Galle E, Schafer J, Bahu MM

2020 HRS; May 7, 2020 Presentation

BeAT-HF 2020 HRS Presentation

Are Intermediate Endpoints Associated With Serious Adverse Cardiovascular Events: Preliminary Results From The BeAT-HF Trial

Zile MR, Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Rogers T, Awad KA

2020 HRS; May 7, 2020 Presentation

BeAT-HF 2020 HRS Presentation

Response To Barostim Therapy By Atrial Fibrillation Status

Zile MR, Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Swarup V

2020 HRS; May 7, 2020 Presentation

BeAT-HF 2019 HRS Late Breaking Clinical Trial Presentation

Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction

Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT

LBCT: 2019 HRS; May 9, 2019 Presentation

BeAT-HF 2019 ESC-HF Late Breaking Clinical Trial Presentation

Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction

Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Zile MR

ESC-HF; May 27, 2019 Presentation

HOPE4HF Trial

Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction

Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC

JACC Heart Fail. 2015;3(6):487-496.

HOPE4HF Trial

Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction: Safety and Efficacy in Patients with and without Cardiac Resynchronization Therapy

Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC

Eur J Heart Fail. 2015;17(10):1066-1074.

HOPE4HF Trial

Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction

Weaver FA, Abraham WT, Little WC, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Madershahian N, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Zile MR

Semin Thorac Cardiovasc Surg. 2016;28(2):320-328.

HOPE4HF Trial

Baroreflex Activation Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction in Patients with and without Coronary Artery Disease

Halbach M, Abraham WT, Butter C, Ducharme A, Klug D, Little WC, Reuter H, Schafer JE, Senni M, Swarup V, Wachter R, Weaver FA, Wilks SJ, Zile MR, Müller-Ehmsen J

Int J Cardiol. 2018;266:187-192.

Mechanism of Action

Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients

Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J

Hypertension. 2010;55(3):619-626.

Mechanism of Action

Effects of Chronic Baroreceptor Stimulation on the Autonomic Cardiovascular Regulation in Patients with Drug-Resistant Arterial Hypertension

Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, Schmidli J, Allemann Y, Delacrétaz E

Hypertension. 2009;54(3):530-536.

Mechanism of Action

Baroreflex activation therapy: Indication and evidence in resistant hypertension and heart failure

Wallbach M, Koziolek MJ, Wachter R

Internist (Berl). 2018;59(10):1011-1020.

A New Approach to Heart Failure Treatment

Make a Difference with BAROSTIM THERAPY

Contact Us